Top Image
Advanced Centre for Treatment Research & Education in Cancer
Facebook Twitter Gmail
Banner Image
Science Sparks @ ACTREC
Date Image 6th June 2022 Vol. No. 11; Issue No. 529

1. Joshi A, Butle A, Hait S, Mishra R, Trivedi V, Thorat R, Choughule A, Noronha V, Prabhash K, Dutt A (2022). Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation. Translational Oncology. 22:101461.

2. Patil V, Menon N, Chatterjee A, Tonse R, Choudhari A, Mahajan A, Puranik A, Epari S, Jadhav M, Pathak S, Peelay Z, Walavalkar R, Muthuluri H, Krishna M, Chandrasekharan A, Pande N, Gupta T, Banavali S, Jalali R (2022). Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial. eClinicalMedicine. 49: 101449.

3. Gupta T, Pervez S, Dasgupta A, Chatterjee A, Epari S, Chinnaswamy G, Jalali R (2022). Omission of upfront craniospinal irradiation in patients with low-risk WNT-pathway medulloblastoma is associated with unacceptably high risk of neuraxial failure. Clinical Cancer Research.

4. Patwardhan S, Patil V, Baheti A, Shukla A, Qureshi S (2022). Relapse of acute lymphoblastic leukemia presenting with ovarian torsion: A rare case report. Pediatric Hematology Oncology Journal

5. Bhat V, Chavan P, Bhat P(2022). Recommendations for COVID-19-related biomedical waste management in health care facilities. Indian Journal of Cancer. 59(1):149-150.

6. Rekhi B, Bal M, Dharavath B, Dutt A, Pai P (2022). A rare case of a low-grade inflammatory leiomyosarcoma/histiocyte-rich rhabdomyoblastic tumor in the neck of an adolescent male. Turkish Journal of Pathology.

7. Gadre S, Manikandan M, Duari P, Chhatar S, Sharma A, Khatri S, Kode J, Barkume M, Kasinathan NK, Nagare M, Patkar M, Ingle A, Kumar M, Kolthur-Seetharam U, Patra M (2022). A rationally designed bimetallic platinum (II)-ferrocene antitumor agent induces non-apoptotic cell death and exerts in vivo efficacy. Chemistry– A European Journal.

8. Mukherjee A, Pednekar CB, Kolke SS, Kattimani M, Duraisamy S, Burli AR, Gupta S, Srivastava S (2022). Insights on proteomics-driven body fluid-based biomarkers of cervical cancer. Proteomes. 10(2):13

9. Parui A, Mishra V, Dutta S, Bhaumik P, Bose K (2022). Inter-subunit crosstalk via PDZ synergistically governs allosteric activation of proapoptotic HtrA2. Structure.

10. Bhattacharjee A, Vishwakarma G, Gajare N, Singh N (2022).Time series analysis using different forecast methods and case fatality rate for COVID-19 pandemic. Regional Science Policy and Practice.

11. Cho HL, Murthy V, Mouw KW, D'Amico AV, Nguyen PL, Leeman JE, Dee EC (2022). Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy. Prostate.

12. Shriyan B, Mehta P, Patil A, Jadhav S, Kumar S, Puri AS, Govalkar R, Krishnamurthy MN, Punatar S, Gokarn A, Khattry N, Gota V (2022). Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia. European Journal of Clinical Pharmacology.

Lipi Ashok Das. 2022. Proteomics studies of a set of predictive and prognostic protein biomarkers in head and neck squamous cell carcinoma (HBNI No.: LIFE09201504012) (Guide: Dr. Ashok Varma)

Site of the Week

SWISSADME allows to compute physicochemical descriptors as well as to predict ADME parameters, pharmacokinetic properties, druglike nature and medicinal chemistry friendliness of one or multiple small molecules to support drug discovery.

desktop Image
Interesting Reads

Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih YP, Leung A, Payne R, Sutcliffe K, Cramer J, Rosenberg SA, Fox BA, Urba WJ, Tran E. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N Engl J Med. 386(22) :2112-2119.

Legends of Science
Hemanta Kumar Majumder Hemanta Kumar Majumder

Hemanta Kumar Majumder obtained his Ph.D. from the Bose Institute, Kolkata, in 1975. His primary research is on the molecular biology of Leishmania donovani, the causative agent of visceral leishmaniasis. His other areas of research includes (i) basic DNA enzymology of topoisomerases, (ii) development of antileishmanial compounds targeted to DNA topoisomerases, (iii) cell death of the parasites induced by DNA topoisomerases inhibitors, and (iv) development of kinetoplast DNA based PCR diagnostics. He is the recipient of the Raja Ramanna Fellowship (2012-2016); Sir J. C. Bose National fellowship (2010-2016). He is a Fellow of the Indian Academy of Sciences, Bengaluru; National Academy of Sciences, Allahabad.

Jayant B Udgaonkar Jayant B Udgaonkar

Jayant Udgaonkar, a biochemist and molecular biologist, obtained his Ph.D. from Cornell University in 1986. He served as an honorary faculty member at the Jawaharlal Nehru Centre for Advanced Scientific Research. In 2017, he joined as a Director of IISER, Pune. He developed methodologies for hydrogen exchange using NMR spectroscopy to explore the intermediates populating protein folding pathways. He demonstrated that not only a single dominant barrier slows down the protein folding, but several distributed small barriers can also influence the reaction. Dr. Udgaonkar was the elected Fellow of the Indian Academy of Sciences in 1997 and; the Indian National Science Academy in 2002. He was the recipient of the SS Bhatnagar Award in 2000.

Upcoming Events
International Hybrid Conference on Traditional and Alternative Medicine

19-20 August, 2022

At Singapore

International Society for Computed Tomography 22nd Annual Symposium

14-16 September, 2022

At San Diego, United States

3rd Congress of Minimally Invasive Surgery

22-24 September, 2022

At Lublin, Poland

Do You Know?

In 1996, Immunologist James Allison, for the first time, showed that blocking a molecule on immune cells called CTLA-4 could cure cancer in mice, which opened a whole new approach to cancer treatment.

back Image
Cancer News
Newly discovered lipid prevents cell death

01 June 2022, EurekAlert

Researchers have now been able to trace the stress response-inhibiting effect of SCD1 back to an indirect product of this enzyme: The membrane lipid PI(18:1/18:1), which is largely composed of a fatty acid produced by SCD1...

NIH study confirms benefit of supplements for slowing age-related macular degeneration

02 June 2022, National Institute of Health

At the end of the five-year AREDS2 study period, the researchers concluded that lutein and zeaxanthin did not increase risk for lung cancer, and that the new formation could reduce the risk of AMD progression by about 26%...

Cancer-killing virus injected into human for the first time in new clinical trial

02 June 2022, MedicalNewsToday

A recent Phase 1 clinical trial has administered a dose of an experimental anticancer drug called CF33-hNIS, or Vaxinia, to the study’s first participant. This novel therapy involves using an oncolytic virus, a type of virus that can infect and kill cancer cells without harming healthy tissue...

� 2022 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)